Select Publications
Journal articles
2022, 'Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease', Experimental Dermatology, 31, pp. 498 - 515, http://dx.doi.org/10.1111/exd.14534
,2022, 'Autoantibody-Mediated Macrophage Responses Provide the Missing Link between Innate and Adaptive Immune Dysfunction in Hidradenitis Suppurativa', Journal of Investigative Dermatology, 142, pp. 747 - 749, http://dx.doi.org/10.1016/j.jid.2021.08.400
,2022, 'Dermatology and wound research: Targeting inflammation through cooperation and collaboration', Wound Practice and Research, 30, pp. 5, http://dx.doi.org/10.33235/wpr.30.1.5
,2022, 'Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review', JAMA Dermatology, 158, pp. 300 - 313, http://dx.doi.org/10.1001/jamadermatol.2021.4926
,2022, 'Antimicrobial peptides in hidradenitis suppurativa: a systematic review*', British Journal of Dermatology, 186, pp. 236 - 244, http://dx.doi.org/10.1111/bjd.20750
,2022, 'The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris', Journal of the American Academy of Dermatology, 86, pp. 322 - 330, http://dx.doi.org/10.1016/j.jaad.2021.07.035
,2022, 'Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry', Journal of the American Academy of Dermatology, 86, pp. 249 - 252, http://dx.doi.org/10.1016/j.jaad.2021.09.016
,2022, 'Cutaneous infection and atopic dermatitis: the importance of early intervention in Indigenous children in Australia', Wound Practice and Research, 30, pp. 34 - 39, http://dx.doi.org/10.33235/wpr.30.1.34-39
,2022, 'High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression', Journal of Allergy and Clinical Immunology, 149, pp. 135 - 144.e12, http://dx.doi.org/10.1016/j.jaci.2021.05.027
,2022, 'Pathergy: a review of potential mechanisms and novel therapeutic targets', Wound Practice and Research, 30, pp. 55 - 61, http://dx.doi.org/10.33235/wpr.30.1.55-61
,2022, 'Pyoderma gangrenosum: a review of the clinical, mechanistic and therapeutic landscape', Wound Practice and Research, 30, pp. 16 - 23, http://dx.doi.org/10.33235/wpr.30.1.16-23
,2022, 'The pathogenesis of hidradenitis suppurativa: Evolving paradigms in a complex disease', Dermatological Reviews, 3, pp. 39 - 49, http://dx.doi.org/10.1002/der2.113
,2021, 'Assessing the responsiveness of sonographic biomarkers to Brodalumab therapy in Hidradenitis Suppurativa', Journal of the European Academy of Dermatology and Venereology, 35, pp. e884 - e887, http://dx.doi.org/10.1111/jdv.17536
,2021, 'Cellular neurothekeoma', International Journal of Women's Dermatology, 7, pp. 835 - 837, http://dx.doi.org/10.1016/j.ijwd.2021.07.011
,2021, 'Clinical considerations in the management of hidradenitis suppurativa in women[Formula presented]', International Journal of Women's Dermatology, 7, pp. 664 - 671, http://dx.doi.org/10.1016/j.ijwd.2021.10.012
,2021, 'A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa', Experimental Dermatology, 30, pp. 1388 - 1397, http://dx.doi.org/10.1111/exd.14141
,2021, 'A systematic review of reported cases of pachyonychia congenita tarda (vol 44, pg 606, 2019)', CLINICAL AND EXPERIMENTAL DERMATOLOGY, 46, pp. 1395 - 1395, http://dx.doi.org/10.1111/ced.14864
,2021, 'An Abscess Is Not a Descriptive Term but an Entity with a Universally Accepted Definition - A Clarification on Semantics - Reply', JAMA Dermatology, 157, pp. 1245 - 1246, http://dx.doi.org/10.1001/jamadermatol.2021.2495
,2021, 'Therapeutic biomarkers in hidradenitis suppurativa: one step closer to the clinic', British Journal of Dermatology, 185, pp. 696 - 697, http://dx.doi.org/10.1111/bjd.20513
,2021, 'Differential profiles of gamma secretase Notch signalling in hidradenitis suppurativa: the need for genotype–endotype–phenotype analysis', British Journal of Dermatology, 185, pp. 636 - 637, http://dx.doi.org/10.1111/bjd.19805
,2021, 'In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes', Journal of Investigative Dermatology, 141, pp. 2197 - 2207, http://dx.doi.org/10.1016/j.jid.2021.02.742
,2021, 'Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab)', JAAD Case Reports, 14, pp. 33 - 36, http://dx.doi.org/10.1016/j.jdcr.2021.05.029
,2021, 'Ultrasound-guided de-roofing of epithelialised tunnels of hidradenitis suppurativa', Australasian Journal of Dermatology, 62, pp. 360 - 363, http://dx.doi.org/10.1111/ajd.13600
,2021, 'The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa', Frontiers in Medicine, 8, http://dx.doi.org/10.3389/fmed.2021.603281
,2021, 'Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa', Journal of Allergy and Clinical Immunology, 147, pp. 2213 - 2224, http://dx.doi.org/10.1016/j.jaci.2020.12.651
,2021, 'Target molecules for future hidradenitis suppurativa treatment', Experimental Dermatology, 30, pp. 8 - 17, http://dx.doi.org/10.1111/exd.14338
,2021, 'Doppler ultrasound-based noninvasive biomarkers in hidradenitis suppurativa: evaluation of analytical and clinical validity', British Journal of Dermatology, 184, pp. 688 - 696, http://dx.doi.org/10.1111/bjd.19343
,2021, 'Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary', JAMA Dermatology, 157, pp. 449 - 455, http://dx.doi.org/10.1001/jamadermatol.2020.5467
,2021, 'Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab', Clinical and Experimental Dermatology, 46, pp. 306 - 313, http://dx.doi.org/10.1111/ced.14448
,2021, 'The erythema Q-score, an imaging biomarker for redness in skin inflammation', Experimental Dermatology, 30, pp. 377 - 383, http://dx.doi.org/10.1111/exd.14224
,2021, 'A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance', Journal of Investigative Dermatology, 141, pp. 316 - 324.e2, http://dx.doi.org/10.1016/j.jid.2020.06.019
,2021, 'The Importance of Methodological Rigor in Proof-of-Concept Clinical Trials: A Lesson from Hidradenitis Suppurativa', Journal of Investigative Dermatology, 141, pp. 429 - 431, http://dx.doi.org/10.1016/j.jid.2020.03.977
,2021, 'Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study', British Journal of Dermatology, 184, pp. 350 - 352, http://dx.doi.org/10.1111/bjd.19478
,2021, 'What's in the pipeline for hidradenitis suppurativa? Emerging and novel therapeutics', Drugs of the Future, 46, pp. 43 - 60, http://dx.doi.org/10.1358/DOF.2021.46.1.3220744
,2021, '700 Vascularization in the deep dermis of hidradenitis suppurativa lesions', Journal of Investigative Dermatology, 141, pp. S121 - S121, http://dx.doi.org/10.1016/j.jid.2021.02.730
,2021, '703 Blood analysis uncovers novel inflammatory, oncologic and cardiovascular biomarkers in psoriasis and Hidradenitis Suppurativa', Journal of Investigative Dermatology, 141, pp. S122 - S122, http://dx.doi.org/10.1016/j.jid.2021.02.733
,2021, 'Cover Image', Experimental Dermatology, 30, http://dx.doi.org/10.1111/exd.14328
,2020, 'Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: Implications for outcome measures and trial design', JAAD International, 1, pp. 208 - 221, http://dx.doi.org/10.1016/j.jdin.2020.09.005
,2020, 'What causes hidradenitis suppurativa ?—15 years after', Experimental Dermatology, 29, pp. 1154 - 1170, http://dx.doi.org/10.1111/exd.14214
,2020, 'Rapid resolution of pyoderma gangrenosum with brodalumab therapy', JAAD Case Reports, 6, pp. 1167 - 1169, http://dx.doi.org/10.1016/j.jdcr.2020.08.033
,2020, 'The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study', Journal of the American Academy of Dermatology, 83, pp. 1341 - 1348, http://dx.doi.org/10.1016/j.jaad.2020.05.007
,2020, 'The value of case reports in pharmacovigilance', British Journal of Dermatology, 183, pp. 795 - 796, http://dx.doi.org/10.1111/bjd.19504
,2020, 'Global Hidradenitis Suppurativa COVID-19 Registry: a registry to inform data-driven management practices', British Journal of Dermatology, 183, pp. 780 - 781, http://dx.doi.org/10.1111/bjd.19345
,2020, 'Malignancy and infection risk during adalimumab therapy in hidradenitis suppurativa', Clinical and Experimental Dermatology, 45, pp. 859 - 865, http://dx.doi.org/10.1111/ced.14264
,2020, 'Anti–Saccharomyces cervisiae antibodies in hidradenitis suppurativa: More than a gut feeling', Journal of Allergy and Clinical Immunology, 146, pp. 458, http://dx.doi.org/10.1016/j.jaci.2020.03.022
,2020, 'Primary imputation methods impact efficacy results in hidradenitis suppurativa clinical trials', Journal of the American Academy of Dermatology, 83, pp. 663 - 665, http://dx.doi.org/10.1016/j.jaad.2020.03.078
,2020, 'The Asia Pacific Hidradenitis Suppurativa (APHiS) foundation: promoting hidradenitis suppurativa research in the Asia Pacific', International Journal of Dermatology, 59, pp. e289 - e290, http://dx.doi.org/10.1111/ijd.14960
,2020, 'Ex Vivo Models and Interpretation of Mechanistic Studies in Hidradenitis Suppurativa', Journal of Investigative Dermatology, 140, pp. 1323 - 1326, http://dx.doi.org/10.1016/j.jid.2020.02.014
,2020, 'Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic, and molecular evidence', JAAD International, 1, pp. 62 - 72, http://dx.doi.org/10.1016/j.jdin.2020.05.005
,2020, 'The contradictory inefficacy of methotrexate in hidradenitis suppurativa: a need to revise pathogenesis or acknowledge disease heterogeneity?', Journal of Dermatological Treatment, 31, pp. 422 - 423, http://dx.doi.org/10.1080/09546634.2019.1601668
,